Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity.

Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity. Abstract Text:

Eiji Tanaka,Yoshihiro Ishino,Akiko Sasaki,Takuro Hasegawa,Mineo Watanabe,Diego A Dalla-Bona,Eizo Yamano,Theo M G J van Eijden,Kazuo Tanne,

The osteoinductive activity induced by recombinant human BMP-2 (rhBMP-2) blunts proportionately as the recipient ages. In order to compensate for this bluntness administration of fibroblast growth factor-2 (FGF-2) has been considered. The aim of this study was to determine whether FGF-2 administration augments osteoinductive activity caused by rhBMP-2 and to evaluate the effect of aging on bone formation induced by coadministration of rhBMP-2 and FGF-2. Sixty-four Wistar strain male rats of 8-week-old (prepubertal) and 16-week-old (postpubertal) received bone defects bilaterally in the parietal bone and the defects were filled by a polylactic acid polyglycolic acid copolymer/gelatin sponge (PGS) impregnated with rhBMP-2 plus 0 ng, 25 ng, and 250 ng FGF-2 (n=10 in each). At 2 weeks after grafting, the new bone volume seemed to be larger in the rhBMP-2+FGF-2 groups than in the rhBMP-2 alone group. At 4 weeks, the new bone formation was linked to the adjacent original bone. In the prepubertal rats, all newly formed bone was similarly calcified. In the postpubertal rats, only the rhBMP-2+25 ng FGF-2 group showed this higher degree of calcification. At 2 weeks, alkaline phosphatase (ALP) activity in the rhBMP-2+25 ng FGF-2 group was significantly (p<0.05) larger than that in the rhBMP-2 group in both prepubertal and postpubertal rats. This result shows that low-dose administration of FGF-2 enhanced the degree of calcification and ALP activity in the rhBMP-2 grafting site especially in the postpubertal rats. Therefore, FGF-2 would be a candidate to compensate for the reduction of osteoinductive activity of rhBMP-2 with aging.

Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity. Publishing Authors By Initials

E Tanaka,Y Ishino,A Sasaki,T Hasegawa,M Watanabe,DA Dalla-Bona,E Yamano,TM van Eijden,K Tanne,

For similar peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research abstracts see: peptides: intercellular signaling peptides and proteins: cytokines: transforming growth factor beta research

PUBMED ID PMID:

MEDLINE DATE:

Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Annals of biomedical engineering

VOLUME: 34

Page Numbers: 717-25

Journal Abbreviation:

ISSN: 0090-6964

DAY: 28

MONTH: 03

YEAR: 2006

Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 361512

Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity. Keywords Mesh Terms:

KEYWORDS: Transforming Growth Factor beta

MESH TERMS: genetics

Chemical & Substance for Abstract: Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity. Information

Substance Name: Fibroblast Growth Factor 2

Registry Number: 103107-01-3

Grant and Affiliation Information for Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity.

AFFILIATION: Department of Orthodontics and Craniofacial Developmental Biology, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan. etanaka@hiroshima-u.ac.jp

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Ann Biomed Eng

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity Related Publications

• A case of anterior open bite with severely narrowed maxillary dental arch and hypertrophic palatine tonsils.
• Biomechanical response of condylar cartilage-on-bone to dynamic shear.
• Cementoblast response to low- and high-intensity ultrasound.
• Congress asks for investigation of FDA resources and staffing.
• Cost of many common treatments varies widely across Europe.
• Downward trend in dementia linked to better education and personal wealth, US study says.
• Dynamic shear behavior of mandibular condylar cartilage is dependent on testing direction.
• Effect of hyperactivity of the lateral pterygoid muscle on the temporomandibular joint disk.
• Endocrine-metabolic effects of unusually long or frequent flying missions in C-130E or C-135B aircraft. SAM-TR-68-24.
• FDA approves use of cloned animals for food.
• FDA is failing to inspect drug and device makers, government reports say.
• FDA may allow drug and device companies to promote "off-label" uses.
• Fibroblast growth factor-2 augments recombinant human bone morphogenetic protein-2-induced osteoinductive activity.
• Four deaths and 350 adverse events lead to US recall of heparin.
• Heterogeneity of fiber characteristics in the rat masseter and digastric muscles.
• Hormone treatment plus radiation delays growth of prostate cancer.
• Impaired glucose metabolism and cerebrovascular diseases.
• Induction of CD44 and MMP expression by hyaluronidase treatment of articular chondrocytes.
• Inhibition of the proliferation of human periodontal ligament fibroblasts by hyaluronidase.
• Interleukin-6 and soluble intercellular adhesion molecule-1 in acute brain ischaemia.
• Modeling of the effect of friction in the temporomandibular joint on displacement of its disc during prolonged clenching.
• NIH needs to raise oversight of conflicts of interest among researchers, report says.
• Pfizer ends advertisements featuring inventor of artificial heart.
• Poor functional status based on the New York Heart Association classification exposes the coronary patient to an elevated risk of ischemic stroke.
• Skeletal anchorage for orthodontic correction of severe maxillary protrusion after previous orthodontic treatment.
• US Congress asked to suspend funding for Planned Parenthood.
• US Institute of Medicine recommends new body to assess what works in health care.
• US gene therapy trial is to restart, despite patient's death.
• US healthcare executive pays back $600m in stock options case.
• US needs universal access to health care, American College of Physicians says.